uniQure, Medison sign Glybera distribution agreement for Israel uniQure and Medison Pharma announced an exclusive distribution agreement under which Medison will market Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency, in Israel and the Palestinian Authority. Medison will also be responsible for obtaining regulatory approval for Glybera in both territories. Financial terms of the agreement have not been disclosed. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal
News For QURE From The Last 14 Days
Check below for free stories on QURE the last two weeks.